Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：233
|
作者：
Verheijen, Remy B. [1 ]
Yu, Huixin [1 ]
Schellens, Jan H. M. [2 ,3 ]
Beijnen, Jos H. [1 ,3 ]
Steeghs, Neeltje [2 ]
Huitema, Alwin D. R. [1 ,4 ]
机构：
[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands
[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands
[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期
关键词：
CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;
D O I：
10.1002/cpt.787
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
引用
收藏
页码：765 / 776
页数：12
相关论文
共 50 条
  • [41] Therapeutic Drug Monitoring of Tyrosine-Kinase Inhibitors in the Treatment of Chronic Myelogenous Leukaemia: Interests and Limits
    Bouchet, Stephane
    Royer, Bernard
    Le Guellec, Chantal
    Titier, Karine
    THERAPIE, 2010, 65 (03): : 213 - 218
  • [42] Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review
    Cardoso, Evelina
    Guidi, Monia
    Blanchet, Benoit
    Schneider, Marie Paule
    Decosterd, Laurent A.
    Buclin, Thierry
    Csajka, Chantal
    Widmer, Nicolas
    THERAPEUTIC DRUG MONITORING, 2020, 42 (01) : 33 - 44
  • [43] Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature
    Fahmy, Alia
    Hopkins, Ashley M.
    Sorich, Michael J.
    Rowland, Andrew
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (07) : 803 - 821
  • [44] Making sense of posaconazole therapeutic drug monitoring: a practical approach
    Ananda-Rajah, Michelle R.
    Grigg, Andrew
    Slavin, Monica A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (06) : 605 - 611
  • [45] Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians Reply
    Peloquin, Charles A.
    Dorman, Susan E.
    Vernon, Andrew
    Migliori, Giovanni Battista
    Nahid, Payam
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (01) : 105 - +
  • [46] Practical information for therapeutic drug monitoring of the most common compounds
    Saint-Marcoux, Franck
    Libert, Frederic
    THERAPIE, 2016, 71 (04): : 405 - 434
  • [47] Practical approach for medical validation of therapeutic drug monitoring results
    Oyaert, Matthijs
    Brandt, Inger
    Vermeersch, Pieter
    Desmet, Koenraad
    Vanstapel, Florent
    Pauwels, Steven
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (03) : E97 - E100
  • [48] THERAPEUTIC DRUG-MONITORING OF CYCLOSPORINE - PRACTICAL APPLICATIONS AND LIMITATIONS
    RODIGHIERO, V
    CLINICAL PHARMACOKINETICS, 1989, 16 (01) : 27 - 37
  • [49] Practical application of therapeutic drug monitoring: A tale of two patients
    Preskorn, Sheldon H.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2008, 14 (05) : 301 - 306
  • [50] Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
    Devendra Desai
    Indian Journal of Gastroenterology, 2024, 43 : 93 - 102
12345